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RESUMO – O docetaxel é um taxano de segunda geração utilizado frequentemente no tratamento de várias neoplasias malignas 
avançadas, nomeadamente no carcinoma da mama. Apresentamos o caso clínico de uma doente de 67 anos com diagnóstico 
de carcinoma ductal invasivo da mama esquerda sob quimioterapia adjuvante com docetaxel, que desenvolveu lesões psoriáti-
cas típicas no tronco e nos membros; a lesão mais representativa localizava-se na proximidade do acesso venoso utilizado para 
administração do fármaco. Não eram conhecidos antecedentes pessoais ou familiares de psoríase. A doente iniciou e manteve 
tratamento com acitretina oral e diproprionato de betametasona/calcipotriol tópicos durante cerca de oito meses, com regressão 
quase total das lesões cutâneas. 
A psoríase fármaco-induzida é uma entidade rara. Os fármacos classicamente associados incluem beta-bloqueantes, interferão 
e os antipalúdicos, entre outros. Demonstramos com o presente caso que o docetaxel deverá ser incluído no grupo de agentes 
farmacológicos potencialmente indutores de psoríase.  
PALAVRAS-CHAVE – Antineoplásicos/efeitos adversos; Erupções por Medicamentos; Psoríase/induzida quimicamente; Taxoi-
des/efeitos adversos.
Postirradiation Multiple Minute Digitate 
Porokeratosis: Case Report 
ABSTRACT – Docetaxel is a second-generation taxane commonly used in the treatment of advanced malignant tumours such as 
breast adenocarcinoma. We describe the case of a 67-year-old female undergoing adjuvant chemotherapy with docetaxel for in-
vasive ductal carcinoma of the left breast presenting with typical psoriatic lesions on the dorsum and limbs - the most representa-
tive of them arising close to the venous access for docetaxel infusion. No personal or family history of psoriasis was reported. The 
patient started and maintained treatment with oral acitretin and topical betamethasone diproprionate/calcipotriol for nearly eight 
months, with almost complete regression of cutaneous lesions. Drug-induced psoriasis is a rare condition. The most commonly re-
ported drugs include beta-blockers, interferon and antimalarials. In this case we demonstrate that docetaxel should be included in 
the group of drugs that can potentially induce psoriasis.
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Docetaxel is a semi-syntethic taxane widely used in the 
treatment of several malignant diseases, namely breast can-
cer, non-small cell lung carcinoma, prostate cancer, gastric 
adenocarcinoma and advanced head and neck cancer.  It in-
duces apoptosis and G2/M cell cycle arrest by inhibiting mi-
crotubule dissociation, acting as a potent antineoplastic agent 




We describe the case of a 67-year-old female, obser-
ved in September 2014 with a progressive and generali-
zed cutaneous eruption, which had become apparent two 
weeks prior to the visit.  The patient had been diagnosed 
with invasive ductal carcinoma of the left breast in April 
2014 and had consequently been submitted to a Madden-
-type left mastectomy and adjuvant chemotherapy. Chemo-
therapy consisted of three initial cycles of 5-fluorouracil, 
epirubicin and cyclophosphamide and three subsequent 
cycles of docetaxel monotherapy; each treatment was ad-
ministered every three weeks.  Cutaneous lesions were no-
ticed approximately one week after the second docetaxel 
infusion, consisting of multiple asymptomatic erythema-
tous plaques with psoriasiform desquamation, mainly dis-
tributed throughout the trunk and proximal limbs (Fig. 1). 
The larger and most typical lesions affected the anterior 
aspect of the right forearm, close to the venous access for 
docetaxel infusion (Fig. 1). No personal or family history 
of psoriasis was reported by the patient, who was otherwi-
se healthy and not taking any other medication. 
The histopathological examination of a skin biopsy 
taken from the right forearm lesion revealed acantho-
sis, parakeratosis and hypogranulosis, overlying a dis-
cretely fibrotic dermis with perivascular mononuclear cell 
infiltrate – these findings were consistent with the clinical 
diagnosis of plaque-type psoriasis (Fig. 2). Further com-
plementary diagnostic exams were negative or within nor-
mal range. 
The diagnosis of docetaxel-induced psoriasis was as-
sumed and the patient started treatment with oral acitretin 
20 mg daily, combined with topical calcipotriol/betame-
thasone diproprionate (o.d.), with a very significant  re-
gression of cutaneous lesions and no significant adverse 
effects were observed, apart from discrete cheilitis. 
Due to the potential risk of psoriasis aggravation, the 
patient did not complete the remaining planned docetaxel 
cycles. Despite the possibility of cross-reactivity, an alter-
native regimen consisting of three weekly cycles of pa-
clitaxel and adjuvant radiotherapy was prescribed, with 
no significant impact on psoriasis, which remained stable 
under specific treatment.  
As no signs of active neoplastic disease were detected 
after completing chemotherapy and radiotherapy, hormo-
nal treatment was promptly started with anastrozol 1mg 
daily. Four months later, following the detection of pleural 
and nodal metastatic disease, the patient started palliative 
chemotherapy with capecitabine and died in May 2015. 
Throughout this period, the patient was kept on acitretin 
20 mg daily with satisfactory control of the dermatitis. 
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Figure 1 - A) Generalized psoriasiform plaques distributed throughout the trunk and limbs. B)  Detail of the larger and most typical psoriasiform plaque 





Cutaneous adverse events have been described in up to 
50% - 70% of patients treated with docetaxel.1 Apart from 
stomatitis, alopecia and hypersensitivity rashes (which are 
equally described both with docetaxel and paclitaxel),2 acral 
erythema/erythrodisesthesia,2 nail changes,2 scleroderma-li-
ke lesions2 and photossensitive eruptions2-4 have been con-
sistently reported in patients under docetaxel chemoterapy. 
Drug-induced psoriasis is classically associated with the 
use of antimalarials, beta-adrenergic blockers, lithium salts, 
tetracyclines or non-steroidal anti-inflammatory drugs. Cyto-
toxic agents, when used, are generally beneficial in patients 
suffering from psoriasis. Docetaxel-induced psoriasis is a very 
rare cutaneous adverse event – it has been previously des-
cribed in three patients with breast adenocarcinoma5,6 and 
squamous cell lung carcinoma.7 None of the other cytostatic 
drugs used in this patient have been previously described as 
triggers in psoriasis; topical and intralesional 5-fluorouracil 
have in fact been used successfully in the treatment of plaque 
psoriasis,8,9 and cyclophosphamide has been anecdotally 
reported in combined treatment of arthropatic psoriasis.10 
Therefore, in our case the emergence of typical psoriatic le-
sions is most likely associated with docetaxel, even though 
we cannot exclude the possible triggering role of the other 
administered drugs and their vehicles. Both the clinical cour-
se of the disease, namely the consistent chronological gap 
between the two events, and the available published data 
validate this association. Also, the exuberance of the pso-
riatic lesions overlying the peripheral venous access area on 
the right volar forearm, which is probably explained by local 
amplification of cutaneous effects of the administered drug 
following vascular extravasation, is a strong evidence of the 
drug’s imputability in the activation of this patient’s psoriasis. 
Interestingly, taxanes (mostly paclitaxel, which has a 
similar chemical structure and clinical effects to those of 
docetaxel11) have been bashfully reported as potential al-
ternatives in topical or systemic treatment of psoriasis.12 
Nevertheless, this case demonstrates that docetaxel is, in 
fact, amongst the drugs that might induce psoriasis, and 
this might represent a major limitation in the use of taxanes 
as a valuable treatment for psoriasis.
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Figure 2 - Histopathological examination detail (H&E, A – 40x, B – 
100x): discrete dermal fibrosis and perivascular mononuclear cell infiltra-
te, underlying an acanthotic and parakeratotic epidermis. 
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